Evidence map›Paper›PMID 31836919›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2020

Chrysophanol suppresses growth and metastasis of T cell acute lymphoblastic leukemia via miR-9/PD-L1 axis.

Junjie Yin, Qingsong Yin, Bo Liang, Ruihua Mi, Hao Ai, Lin Chen, Xudong Wei

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Frontiers in pharmacology · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Junjie YinDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou City, 450008, Henan Province, China.
Qingsong YinDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou City, 450008, Henan Province, China. yinqingsong12@126.com.ORCID http://orcid.org/0000-0002-1703-1175
Bo LiangDepartment of Hematology, The Central Hospital of Xinxiang, Xinxiang City, 453002, Henan Province, China.
Ruihua MiDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou City, 450008, Henan Province, China.
Hao AiDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou City, 450008, Henan Province, China.
Lin ChenDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou City, 450008, Henan Province, China.
Xudong WeiDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou City, 450008, Henan Province, China.
Zhengzhou University · CNXinxiang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell acute lymphoblastic leukemia (T-ALL) was a malignant lymphoma. Therefore, the development of novel therapeutic agents against T-ALL is imperative. Previous studies have shown that chrysophanol (CHL), an anthraquinone compound isolated from the Rheum palmatum L., exerts anti-proliferative and anti-metastatic effects in multiple malignant tumors. However, the effect of CHL on the progression of TALL is poorly understood. The aim of this study was to explore the role of CHL in the biological behavior of T-ALL cells and determine its underlying mechanism. Both T-ALL cell lines (Jurkat and TALL-104) were treated with CHL. The proliferation, apoptosis, migration, and invasion of T-ALL cells were determined by CCK-8, flow cytometry, wound healing, and Transwell assay, respectively. Western blot and RT-qPCR were applied to examine gene expression. The dual-luciferase reporter gene assay was employed to examine the regulation mechanism of miR-9 and PD-L1. A T-ALL xenograft model also was used to examine the effect of CHL on the tumor growth and metastasis in vivo. CHL treatment significantly inhibited the proliferation, migration, and invasion ability of both Jurkat and TALL-104 cells and induced cell apoptosis and the expression of miR-9. Moreover, miR-9 was proved to target PD-L1 by binding to its 3'-untranslated region (UTR). Mechanically, pretreated with PD-L1 inhibitor could augment the anti-proliferation and anti-metastatic effect of CHL, while miR-9-silenced alleviated this effect. Consistent with in vitro studies, CHL significantly suppressed the growth and metastasis of tumor in vivo. Our finding uncovers the antitumorigenic effect of CHL in T-ALL progression through upregulating the expression of miR-9 and suppressing PD-L1 expression, which may provide a new potential strategy for T-ALL clinical treatment.

Indexed as

ChrysophanolGrowth and metastasismiR-9PD-L1T cell acute lymphoblastic leukemia

Identifiers

PMID31836919
OpenAlexW2996410570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.